Praxis Precision Medicines (PRAX) is trading higher as investors continue to reprice the company around its late-stage regulatory path for ulixacaltamide in essential tremor. The key driver remains the FDA’s April 14, 2026 acceptance of Praxis’ New Drug Application, which established a clear review timeline and reduced perceived regulatory uncertainty by indicating no advisory committee meeting is expected.

On April 14, 2026, Praxis said the FDA accepted the ulixacaltamide HCl NDA for the treatment of essential tremor in adults and assigned a Prescription Drug User Fee Act (PDUFA) target action date of January 29, 2027. The company also stated the agency is not planning to hold an advisory committee meeting, a detail that traders often interpret as incremental de-risking for the review process.

After a major regulatory headline, biopharma stocks frequently see follow-through buying and position adjustments over subsequent sessions as investors digest implications for probability of approval, commercialization timelines, and financing needs. With a defined PDUFA date now in place, PRAX trading can become increasingly catalyst-driven, with attention shifting to labeling expectations, launch preparation, and any incremental disclosures tied to the Essential3 program that supported the filing.